Financing ·
DNA X, Inc. filed an amendment to update disclosure regarding the sale of remaining Series B Preferred Stock shares…
SONMDNA X, Inc.
DNA X, Inc. filed an amendment to update disclosure regarding the sale of remaining Series B Preferred Stock shares under a Purchase Agreement on August 7, 2026. The company issued 416,667 shares in exchange for $2.5 million in cash proceeds. Management states that this transaction brings stockholders' equity above the $2.5 million minimum requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1). The filing includes a pro forma summary of stockholders' equity, projecting an ending balance of $5,840 thousand as of August 7, 2026. The company is awaiting formal determination from Nasdaq regarding compliance with the Equity Rule and intends to provide an update upon receipt. DNA X, Inc. operates in the biotechnology industry, specializing in genomic sequencing technologies.